// App-Quantinova.ai

1670P : Serial genotypic characterization of circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing treatment with abiraterone acetate (abi) or enzalutamide (enza)

Researchers

Presenter

  • N.Dizman

Principal Investigators

  • J.Patel

  • B.Foulk

  • D.A.Smirnov

  • J.Hsu

  • P.Twardowski

  • M.Kortylewski

  • V.Bhargava

  • J.Jones

  • S.K.Pal

Medical Centers

  • Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, CA, USA

  • Janssen Pharmaceuticals, Janssen Pharmaceuticals, Spring House, PA, USA

  • Department of Cancer Immunotherapeutics and Tumor Immunology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Epithelial Cell Adhesion Molecule

Drug/Treatment

  • CB-7598

  • Enzalutamide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved